Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering

J Pediatr Hematol Oncol. 2017 Apr;39(3):217-222. doi: 10.1097/MPH.0000000000000786.

Abstract

This case report details a unique case of acute, reversible liver failure in a 12-year-old male with sickle cell anemia on chronic transfusion protocol and deferasirox chelation. There is substantial literature documenting deferasirox-induced renal injury, including Fanconi syndrome, but less documentation of hepatic toxicity and few reports of hepatic failure. The case highlights the importance of close monitoring of ferritin, bilirubin, and transaminases for patients on deferasirox.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / therapy
  • Benzoates / therapeutic use
  • Benzoates / toxicity*
  • Bilirubin
  • Blood Transfusion
  • Child
  • Deferasirox
  • Ferritins
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Iron Chelating Agents / toxicity
  • Liver Failure, Acute / chemically induced
  • Liver Failure, Acute / etiology*
  • Male
  • Transaminases
  • Triazoles / therapeutic use
  • Triazoles / toxicity*

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Ferritins
  • Transaminases
  • Bilirubin
  • Deferasirox